Skip to main content
Premium Trial:

Request an Annual Quote

Biocept BRAF Liquid Biopsy Test

Biocept has launched a blood-based BRAF mutation test to help physicians identify melanoma patients who might benefit from currently available targeted therapies. According to the company, because of the high sensitivity of the assay, it could also be used to monitor patients' response to treatment and the progression of disease during the course of therapy.

A quantitative assay, the BRAF test joins Biocept's existing portfolio of liquid biopsy tests for breast, lung and gastric cancer biomarkers. The firm's platform analyzes circulating tumor DNA in circulating tumor cells and plasma. 

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.